US EditionPublished • loading... • Updated
FDA Grants Breakthrough Status to Larimar’s Nomlabofusp
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FDA Grants Breakthrough Status to Larimar’s Nomlabofusp
BALA CYNWYD, PA — Larimar Therapeutics Inc. (Nasdaq: LRMR) said the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to nomlabofusp for the treatment of adults and children with Friedreich’s ataxia, based on preliminary clinical data from an ongoing open-label study. The clinical-stage biotechnology company said the designation and recent written feedback from the FDA followed a Support for Clinical Trials Advancing…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
